- Home
- ASC vs ERAS Comparison
ASC vs ERAS Comparison
Compare ASC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASC
- ERAS
- Stock Information
- Founded
- ASC 2010
- ERAS 2018
- Country
- ASC Bermuda
- ERAS United States
- Employees
- ASC N/A
- ERAS N/A
- Industry
- ASC Marine Transportation
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- ASC Consumer Discretionary
- ERAS Health Care
- Exchange
- ASC Nasdaq
- ERAS Nasdaq
- Market Cap
- ASC 617.6M
- ERAS 719.0M
- IPO Year
- ASC 2013
- ERAS 2021
- Fundamental
- Price
- ASC $11.77
- ERAS $2.67
- Analyst Decision
- ASC Buy
- ERAS Strong Buy
- Analyst Count
- ASC 3
- ERAS 5
- Target Price
- ASC $20.00
- ERAS $6.10
- AVG Volume (30 Days)
- ASC 897.0K
- ERAS 1.7M
- Earning Date
- ASC 11-06-2024
- ERAS 11-12-2024
- Dividend Yield
- ASC 12.91%
- ERAS N/A
- EPS Growth
- ASC 6.23
- ERAS N/A
- EPS
- ASC 3.55
- ERAS N/A
- Revenue
- ASC $422,624,000.00
- ERAS N/A
- Revenue This Year
- ASC N/A
- ERAS N/A
- Revenue Next Year
- ASC N/A
- ERAS N/A
- P/E Ratio
- ASC $3.31
- ERAS N/A
- Revenue Growth
- ASC N/A
- ERAS N/A
- 52 Week Low
- ASC $11.59
- ERAS $1.51
- 52 Week High
- ASC $23.44
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- ASC 10.41
- ERAS 43.56
- Support Level
- ASC $11.85
- ERAS $2.59
- Resistance Level
- ASC $12.23
- ERAS $3.19
- Average True Range (ATR)
- ASC 0.46
- ERAS 0.20
- MACD
- ASC -0.10
- ERAS -0.02
- Stochastic Oscillator
- ASC 6.21
- ERAS 20.13
About ASC Ardmore Shipping Corporation
Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The Company operates its business in one operating segment, the transportation of refined petroleum products and chemicals.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.